Literature DB >> 11454425

Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation.

M Debiec-Rychter1, J Lasota, M Sarlomo-Rikala, R Kordek, M Miettinen.   

Abstract

Gastrointestinal stromal tumors (GISTs) are distinctive, KIT positive mesenchymal neoplasms. The genetic alterations leading to the malignant behavior of these tumors are not well known. In this study, we looked for recurrent numerical chromosomal changes, which may be associated with malignant GISTs, using interphase fluorescence in situ hybridization (FISH). Fourteen malignant primary tumors and two intra-abdominal recurrences were analyzed. Nine benign tumors were studied for comparison. In all cases, the presence of mutations in exons 9, 11 and 13 of the KIT gene were evaluated. Sixteen centromeric enumeration probes (CEP) for chromosomes 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, and X and three locus specific probes (LSI) for 22q11.2 (BCR-locus), 13q14 (RB1-locus) and 14q32 (IgH-locus) were used. The most common changes seen in malignant GISTs were losses of 14q32 and 22q11. However, these changes were commonly detected in benign tumors and represent early changes related to the pathogenesis of GISTs. Losses of chromosomes 1 and 9 were the only recurrent numerical changes seen exclusively in malignant GISTs. Other recurrent numerical changes seen predominantly in malignant tumors were gain of chromosome 8 and losses of chromosomes 7 and 15. The concurrent loss of chromosome 7 and gain of chromosome 8 (in 4 cases) was never seen together with loss of chromosomes 9 or 15 and only once with loss of chromosome 1. Mutations in KIT were found in the majority of malignant GISTs (64%) confirming a previously shown correlation between presence of such mutations and malignancy. KIT mutations were seen in four of five malignant GISTs with loss of chromosome 9, but only in one of four malignant tumors with loss of chromosome 1. These observations may reflect the different pathways leading to malignant transformation of GISTs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454425     DOI: 10.1016/s0165-4608(01)00395-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  22 in total

1.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.

Authors:  R Penzel; S Aulmann; M Moock; M Schwarzbach; R J Rieker; G Mechtersheimer
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

3.  Extramammary myofibroblastoma is genetically related to spindle cell lipoma.

Authors:  Francesca Maggiani; Maria Debiec-Rychter; Guy Verbeeck; Raf Sciot
Journal:  Virchows Arch       Date:  2006-05-20       Impact factor: 4.064

Review 4.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

5.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Authors:  Christopher L Corless; Laura McGreevey; Andrea Haley; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 6.  Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.

Authors:  Chandu M V de Silva; Robin Reid
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

Review 7.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

Review 8.  Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Authors:  Mrinal M Gounder; Robert G Maki
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-30       Impact factor: 3.333

9.  [Atypical lipomatous tumors of the stomach. Clinical, morphological and molecular findings].

Authors:  C Kuhnen; T Mentzel; W Haarmann; U Schwegler; R Sciot; M Debiec-Rychter
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

Review 10.  Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.

Authors:  Gunhild Mechtersheimer; Gerlinde Egerer; Manfred Hensel; Ralf J Rieker; Martin Libicher; Thomas Lehnert; Roland Penzel
Journal:  Virchows Arch       Date:  2004-01-20       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.